OR WAIT null SECS
CancerNetwork® speaks with Kami Maddocks, MD, in part 2 of a 3-part series on CD19–directed agents and other second-line agent for relapsed/refractory diffuse large B-cell lymphoma.
CancerNetwork® spoke with Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, about CD19-directed agents, avoiding rechallenging with rituximab (Rituxan), and outcomes with second-line therapy for transplant-ineligible patients with diffuse large B-cell lymphoma.
Visit cancernetwork.com to check out the first episode of this 3-part series here.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.